“Protecting the health and
informed consent rights of children since 1982.”
From Michael Belkin:
Too bad preventing vaccine adverse reactions isn’t
lucrative.
Decision Resources Study Evaluates Promising Vaccines in
Development to Treat Influenza
Waltham, MA/January 15, 2001-Decision Resources, Inc., has
just published a new study titled Influenza A and B. The primary cause of
clinical influenza-the influenza A and B viruses-are highly infectious
particles that can rapidly disseminate in a population. Because of influenza’s unpredictability,
its historical toll on human life, and its potential for causing high morbidity
and mortality, this disease merits increased interest from both health care
systems and drug development companies.
Of the therapies in development, the most promising are
several emerging vaccines, including Chiron’s adjuvanted vaccine, Fluad;
Aventis Pasteur’s recombinant neuraminidase (NA)-enhanced vaccine, Fluzone +
baculovirus derived rNA; and Aviron/Wyeth-Lederle’s intranasal, live-attenuated
vaccine, Flumist. In addition, a promising new NA inhibitor, Ortho-McNeil/R.W. Johnson Pharmaceuticals’ RWJ-270201, is in
Phase II/III trials. Thought leaders interviewed for this study say these novel
vaccines promise the advantages of improved effectiveness and easier
administration, while RWJ-270201 offers once-daily administration and an
improved side-effect profile.
Sales of influenza vaccines in the major markets topped
$550 million in 1999. We expect sales to exceed $1 billion in 2009, reflecting
annual growth of 7%. We estimate that sales of antivirals in the major
pharmaceutical markets will exceed $166 million in 2009, with greater growth
during the 1999-2004 segment (estimated at more than 10% per year), driven mainly
by increased utilization of the NA inhibitors. The highest absolute growth in sales
will occur in the United States, where there has generally been a higher uptake
of antiviral therapy for influenza. Growth in all the markets will be fueled by
the following factors:
Wider recognition among physicians of the utility of these
agents. Increased patient awareness of
the importance of seeking treatment early, when NA inhibitors are effective.
Increased patient demand for these agents.
Influenza A and B is part of Infectious Disease, one of
six Pharmacor services that evaluate the commercial potential of drugs in
research and development.
Decision Resources, Inc., is a world leader in research
publications, advisory services, and consulting designed to help clients shape
strategy, allocate resources, and master their chosen markets. Founded as a
subsidiary of Arthur D. Little, Inc., the company has provided strategic
information services for 30 years, assessing industry trends in the
international health care and pharmaceutical industries.
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550
(fax), or
sama@dresources.com (e-mail). In Europe, contact Francoise
Bidart,
+32.2.351.4082 (telephone), +32.2.351.2347 (fax), or
fbidart@decisionresources.be (e-mail). In
Japan, contact Makiko Yoshimoto
+81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp
(e-mail).
News@909shot.com is a free service of the National Vaccine
Information
Center and is supported through membership donations. Learn more about
vaccines, diseases and how to protect your informed
consent rights http://www.909shot.com
To sign up for a free e-mail subscription
http://www.909shot.com/emaillist.htm
To unsubscribe from this list, send an email to news-request@909shot.com
and type UNSUBSCRIBE in the body of the email.
NVIC is funded through individual membership donations and
does not receive government funding. Barbara Loe Fisher, President and
Co-founder. NOTE: This is not an
interactive e-mail list. Please do not respond to messages.
ALL
INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR
GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE
KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED
AS PROVIDING MEDICAL OR LEGAL ADVICE. THE DECISION WHETHER OR NOT TO
VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU
ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.